Advanced

Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.

Gustavsson, Anders; Jönsson, Linus; Parmler, Johan; Andreasen, Niels; Wattmo, Carina LU ; Wallin, Åsa LU and Minthon, Lennart LU (2012) In European Journal of Health Economics 13(5). p.561-568
Abstract
BACKGROUND/AIMS: Improved data and methods are needed for modeling disease progression in Alzheimer's disease (AD) for economic evaluation of treatments. The aim is to estimate prediction models for long-term AD progression and subsequently economic outcomes.



METHODS: Three-year follow-up data on 435 patients treated with the cholinesterase inhibitor donepezil in clinical practise were analyzed. Regression models were estimated for long-term prediction of decline in cognitive function (ADAS-cog) and activities in daily living (ADL) ability, risk of institutionalization and costs of care.



RESULTS: The cognitive deterioration was estimated at between 1.6 and 4 ADAS-cog points per every 6 months,... (More)
BACKGROUND/AIMS: Improved data and methods are needed for modeling disease progression in Alzheimer's disease (AD) for economic evaluation of treatments. The aim is to estimate prediction models for long-term AD progression and subsequently economic outcomes.



METHODS: Three-year follow-up data on 435 patients treated with the cholinesterase inhibitor donepezil in clinical practise were analyzed. Regression models were estimated for long-term prediction of decline in cognitive function (ADAS-cog) and activities in daily living (ADL) ability, risk of institutionalization and costs of care.



RESULTS: The cognitive deterioration was estimated at between 1.6 and 4 ADAS-cog points per every 6 months, increasing with disease severity. Cognitive function was an important predictor of ADL-ability, which itself was the most important predictor of the risk of institutionalization and costs of care. Combining all models in a cross-validation process generated accurate predictions of costs of care at each 6 months follow-up.



CONCLUSION: The proposed methods for representing AD progression and economic outcomes can be used in micro-simulation models for the economic evaluation of new treatments. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Health Economics
volume
13
issue
5
pages
561 - 568
publisher
Springer
external identifiers
  • wos:000308029500004
  • scopus:84865622054
ISSN
1618-7601
DOI
10.1007/s10198-011-0334-y
language
English
LU publication?
yes
id
d8953f60-85cf-425a-89e4-14b4a6901a1d (old id 3046737)
date added to LUP
2012-12-17 11:33:52
date last changed
2017-05-28 03:13:18
@article{d8953f60-85cf-425a-89e4-14b4a6901a1d,
  abstract     = {BACKGROUND/AIMS: Improved data and methods are needed for modeling disease progression in Alzheimer's disease (AD) for economic evaluation of treatments. The aim is to estimate prediction models for long-term AD progression and subsequently economic outcomes.<br/><br>
<br/><br>
METHODS: Three-year follow-up data on 435 patients treated with the cholinesterase inhibitor donepezil in clinical practise were analyzed. Regression models were estimated for long-term prediction of decline in cognitive function (ADAS-cog) and activities in daily living (ADL) ability, risk of institutionalization and costs of care.<br/><br>
<br/><br>
RESULTS: The cognitive deterioration was estimated at between 1.6 and 4 ADAS-cog points per every 6 months, increasing with disease severity. Cognitive function was an important predictor of ADL-ability, which itself was the most important predictor of the risk of institutionalization and costs of care. Combining all models in a cross-validation process generated accurate predictions of costs of care at each 6 months follow-up.<br/><br>
<br/><br>
CONCLUSION: The proposed methods for representing AD progression and economic outcomes can be used in micro-simulation models for the economic evaluation of new treatments.},
  author       = {Gustavsson, Anders and Jönsson, Linus and Parmler, Johan and Andreasen, Niels and Wattmo, Carina and Wallin, Åsa and Minthon, Lennart},
  issn         = {1618-7601},
  language     = {eng},
  number       = {5},
  pages        = {561--568},
  publisher    = {Springer},
  series       = {European Journal of Health Economics},
  title        = {Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.},
  url          = {http://dx.doi.org/10.1007/s10198-011-0334-y},
  volume       = {13},
  year         = {2012},
}